Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epilepsy | 9 | 2024 | 110 | 1.850 |
Why?
|
| Seizures | 6 | 2023 | 143 | 1.500 |
Why?
|
| Confusion | 2 | 2019 | 17 | 1.180 |
Why?
|
| Vision Disorders | 2 | 2019 | 67 | 1.130 |
Why?
|
| Status Epilepticus | 3 | 2023 | 25 | 1.040 |
Why?
|
| Drug Resistant Epilepsy | 4 | 2024 | 19 | 0.780 |
Why?
|
| Electroencephalography | 4 | 2024 | 151 | 0.750 |
Why?
|
| Tongue | 1 | 2020 | 16 | 0.670 |
Why?
|
| Deglutition | 1 | 2020 | 19 | 0.660 |
Why?
|
| Mouth | 1 | 2020 | 34 | 0.660 |
Why?
|
| Sleep Deprivation | 1 | 2020 | 16 | 0.640 |
Why?
|
| Heart Arrest | 1 | 2021 | 177 | 0.580 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2017 | 3 | 0.540 |
Why?
|
| Psychotic Disorders | 1 | 2018 | 159 | 0.500 |
Why?
|
| Patient Readmission | 5 | 2021 | 432 | 0.490 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 108 | 0.480 |
Why?
|
| Hospitalization | 4 | 2020 | 1368 | 0.470 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2016 | 127 | 0.460 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 166 | 0.460 |
Why?
|
| Fibrinolytic Agents | 1 | 2016 | 173 | 0.450 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 695 | 0.330 |
Why?
|
| Stroke | 3 | 2020 | 1196 | 0.300 |
Why?
|
| Treatment Outcome | 3 | 2023 | 5691 | 0.270 |
Why?
|
| Humans | 21 | 2024 | 64243 | 0.260 |
Why?
|
| Retrospective Studies | 6 | 2023 | 6726 | 0.250 |
Why?
|
| Risk Factors | 6 | 2021 | 5339 | 0.230 |
Why?
|
| Middle Aged | 8 | 2020 | 17899 | 0.210 |
Why?
|
| New York | 2 | 2021 | 143 | 0.210 |
Why?
|
| Databases, Factual | 4 | 2020 | 856 | 0.200 |
Why?
|
| Epilepsies, Partial | 1 | 2023 | 18 | 0.200 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2016 | 108 | 0.200 |
Why?
|
| Aged | 8 | 2020 | 14648 | 0.190 |
Why?
|
| Comorbidity | 3 | 2021 | 1118 | 0.180 |
Why?
|
| Female | 10 | 2024 | 33351 | 0.180 |
Why?
|
| First Aid | 1 | 2020 | 6 | 0.170 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 163 | 0.170 |
Why?
|
| International Classification of Diseases | 2 | 2018 | 135 | 0.170 |
Why?
|
| Brain Stem Infarctions | 1 | 2020 | 4 | 0.160 |
Why?
|
| Pons | 1 | 2020 | 15 | 0.160 |
Why?
|
| Coma | 1 | 2020 | 13 | 0.160 |
Why?
|
| Retinal Artery Occlusion | 1 | 2020 | 5 | 0.160 |
Why?
|
| Bacterial Proteins | 3 | 2016 | 775 | 0.160 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 158 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 5520 | 0.150 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 220 | 0.150 |
Why?
|
| Lorazepam | 1 | 2018 | 8 | 0.140 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2018 | 14 | 0.140 |
Why?
|
| Public Health | 1 | 2020 | 186 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 65 | 0.140 |
Why?
|
| Male | 8 | 2024 | 30295 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 180 | 0.140 |
Why?
|
| Mood Disorders | 1 | 2018 | 76 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 462 | 0.140 |
Why?
|
| Patient Discharge | 2 | 2018 | 507 | 0.130 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 107 | 0.130 |
Why?
|
| United States | 5 | 2024 | 7923 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2017 | 125 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 2217 | 0.130 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 267 | 0.130 |
Why?
|
| Child | 5 | 2024 | 4583 | 0.130 |
Why?
|
| Adult | 7 | 2023 | 17117 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 735 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 1 | 2016 | 32 | 0.120 |
Why?
|
| Brain Ischemia | 2 | 2020 | 421 | 0.120 |
Why?
|
| Type III Secretion Systems | 1 | 2016 | 4 | 0.120 |
Why?
|
| Salmonella typhimurium | 1 | 2016 | 86 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2016 | 498 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2016 | 607 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 201 | 0.110 |
Why?
|
| Antigens, Bacterial | 1 | 2016 | 200 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 221 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2016 | 188 | 0.100 |
Why?
|
| Cell Membrane | 2 | 2016 | 501 | 0.100 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 220 | 0.090 |
Why?
|
| Registries | 1 | 2016 | 885 | 0.090 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2011 | 38 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 54 | 0.090 |
Why?
|
| Liposomes | 1 | 2011 | 107 | 0.080 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 100 | 0.080 |
Why?
|
| Time Factors | 1 | 2016 | 3724 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 2737 | 0.060 |
Why?
|
| Animals | 2 | 2020 | 20962 | 0.050 |
Why?
|
| Censuses | 1 | 2023 | 17 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2023 | 163 | 0.050 |
Why?
|
| Health Facilities | 1 | 2022 | 43 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2022 | 202 | 0.040 |
Why?
|
| Hematoma, Subdural | 1 | 2020 | 10 | 0.040 |
Why?
|
| Hernia | 1 | 2020 | 14 | 0.040 |
Why?
|
| Hepatorenal Syndrome | 1 | 2020 | 2 | 0.040 |
Why?
|
| Palliative Care | 1 | 2022 | 239 | 0.040 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2020 | 15 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 21 | 0.040 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 10 | 0.040 |
Why?
|
| Peritonitis | 1 | 2020 | 43 | 0.040 |
Why?
|
| Research Design | 1 | 2022 | 583 | 0.040 |
Why?
|
| Protein Binding | 2 | 2016 | 1619 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 81 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 423 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 193 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2021 | 756 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 587 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 818 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2016 | 101 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 108 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 2016 | 53 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 112 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1407 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 1176 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 319 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2016 | 182 | 0.030 |
Why?
|
| Cell Death | 1 | 2016 | 286 | 0.030 |
Why?
|
| Smoking | 1 | 2020 | 861 | 0.030 |
Why?
|
| Depression | 1 | 2021 | 909 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2016 | 540 | 0.030 |
Why?
|
| Gold | 1 | 2016 | 233 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2478 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 1494 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1001 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 2604 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 86 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 92 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 1187 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2011 | 63 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2011 | 81 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 3315 | 0.020 |
Why?
|
| Biological Transport | 1 | 2011 | 291 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 405 | 0.020 |
Why?
|
| Cryoelectron Microscopy | 1 | 2011 | 208 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2238 | 0.020 |
Why?
|